• Statement

    FINAL NIST Oral Testimony – John Stanford, Incubate

    We're here today to lend our strong support to the proposed clarification of the appropriate use of "march-in" authority under Bayh Dole. This authority was never intended to be used a price-control mechanism, as such an interpretation would destabilize the IP protections that drive America's global biopharmaceutical leadership

  • Blog

    Mergers and Acquisitions: A Key Driver of VC Investment in Healthcare

    The drug pricing debate is a worthy one. We have to have open discussions about maximizing innovation and access. But half-written reports from a region that is home to the economic benefits of this industry do little to move that debate forward.

  • Article

    March-In is Not the Answer

    There is one strategy, however, that is likely to make things worse; overriding patents on drugs developed with the help of federally funded research. This so-called "march in" option is not a good idea.

  • Statement

    Most Favored Nation (MFN) Model Interim Final Rule with Comment Period

    Incubate writes to share our strong concerns with the interim final rule (IFR) implementing the Most Favored Nation (MFN) Model. We request the Biden Administration withdraw this rule.

  • Infographic

    Anti Microbial Resistance Whitepaper

    From the Partnership to Fight Infectious Disease

  • Statement

    Venture Capitalist Letter Addressing President Trump’s MFN EO

    early stage life sciences community, write in strong opposition to the recently signed Executive Order (EO), Lowering Drug Prices by Putting America First.

  • Article

    Ensuring U.S. Biopharmaceutical Competitiveness

    By Stephen Ezell, Information Technology and Innovation Foundation